Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total value of $104,986.00. Following the transaction, the senior vice president now owns 10,169 shares of the company’s stock, valued at approximately $142,366. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jamie Christensen also recently made the following trade(s):

  • On Wednesday, October 4th, Jamie Christensen sold 4,000 shares of Mirati Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $56,000.00.
  • On Friday, September 15th, Jamie Christensen sold 770 shares of Mirati Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $9,240.00.

Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) opened at $14.05 on Friday.

Mirati Therapeutics (NASDAQ:MRTX) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.16. equities research analysts predict that Mirati Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Jamie Christensen Sells 7,499 Shares of Mirati Therapeutics, Inc. (MRTX) Stock” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/jamie-christensen-sells-7499-shares-of-mirati-therapeutics-inc-mrtx-stock/1680530.html.

A number of hedge funds have recently bought and sold shares of the stock. Broadfin Capital LLC boosted its holdings in Mirati Therapeutics by 19.1% in the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after buying an additional 400,000 shares during the last quarter. Sabby Management LLC boosted its holdings in Mirati Therapeutics by 2.1% in the 2nd quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock worth $921,000 after buying an additional 5,365 shares during the last quarter. Royce & Associates LP boosted its holdings in Mirati Therapeutics by 88.7% in the 2nd quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock worth $917,000 after buying an additional 118,063 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Mirati Therapeutics by 53.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock worth $728,000 after buying an additional 69,377 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Mirati Therapeutics in the 1st quarter worth about $854,000. Institutional investors own 59.95% of the company’s stock.

MRTX has been the subject of a number of recent research reports. Citigroup Inc. reiterated a “buy” rating and set a $16.00 price objective (up previously from $8.00) on shares of Mirati Therapeutics in a research note on Tuesday, September 19th. SunTrust Banks, Inc. restated a “buy” rating and set a $13.00 target price on shares of Mirati Therapeutics in a research report on Monday, October 2nd. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Mirati Therapeutics in a research report on Thursday, October 12th. Jefferies Group LLC set a $5.00 target price on Mirati Therapeutics and gave the company a “hold” rating in a research report on Friday, August 4th. Finally, Leerink Swann raised their target price on Mirati Therapeutics from $7.00 to $9.00 and gave the company a “market perform” rating in a research report on Friday, September 15th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. Mirati Therapeutics has a consensus rating of “Hold” and a consensus price target of $14.14.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.